Archive


Category: BioDelivery Sciences International

  • Collegium agrees $604m buyout of pain specialist BDSI

    Collegium Pharma has expanded its pain franchise though a deal to acquire BioDelivery Sciences International (BDSI), which has three FDA-approved drugs and a new migraine therapy due to launch in the coming weeks. Collegium – which sells opioid analgesics under the Xtampza (oxycodone) and Nucynta (tapentadol) brands – has agreed to pay $5.60 per share […]